Parkinson's disease and the risk of cerebrovascular pathology

Movement Disorders

Volumn 27, Issue 12, 2012, Pages 1471-1472

  Morley, James F ^a   Duda, John E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

AGING; ATHEROSCLEROSIS; BLOOD PRESSURE; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; DEATH; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; EDITORIAL; GAIT DISORDER; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFARCTION; MOOD DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RIGIDITY; RISK; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; TREMOR; URINE INCONTINENCE; VASCULAR DISEASE; WHITE MATTER LESION;

BRAIN; CEREBRAL SMALL VESSEL DISEASES; FEMALE; HUMANS; MALE; PARKINSON DISEASE;

EID: 84867743267     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25179     Document Type: Editorial

References (27)

1. Schwartz RS, Halliday GM, Cortado DJ, Kril JJ. Small-vessel disease in patients with parkinson disease: A clinicopathologic study. Mov Disord 2012; 27:1506-1512.
2. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of michigan mortality data, 1970 to 1990. Neurology 1994; 44: 1865-1868.
3. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995; 58: 293-299.
4. Struck LK, Rodnitzky RL, Dobson JK. Stroke and its modification in Parkinson's disease. Stroke 1990; 21: 1395-1399.
5. Nataraj A, Rajput AH. Parkinson's disease, stroke, and related epidemiology. Mov Disord 2005; 20: 1476-1480.
6. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol 2003; 105: 415-419.
7. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006; 21: 223-229.
8. Levine RL, Jones JC, Bee N. Stroke and Parkinson's disease. Stroke 1992; 23: 839-842.
9. Mastaglia FL, Johnsen RD, Kakulas BA. Prevalence of stroke in Parkinson's disease: a postmortem study. Mov Disord 2002; 17: 772-774.
10. Ghebremedhin E, Rosenberger A, Rub U, et al. Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J Neuropathol Exp Neurol 2010; 69: 442-448.
11. Nanhoe-Mahabier W, de Laat KF, Visser JE, Zijlmans J, de Leeuw FE, Bloem BR. Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 2009; 5: 533-541.
12. Alves G, Kurz M, Lie SA, Larsen JP. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov Disord 2004; 19: 1087-1092.
13. Scigliano G, Ronchetti G, Girotti F, Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord 2009; 15: 138-143.
14. Scigliano G, Ronchetti G, Girotti F, Musicco M. Levodopa reduces risk factors for vascular disease in parkinsonian patients. J Neurol 2008; 255: 1266-1267.
15. Durrieu G, Senard JM, Rascol O, et al. Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243). Neurology 1990; 40: 707-709.
16. Mannelli M, Ianni L, Lazzeri C, et al. In vivo evidence that endogenous dopamine modulates sympathetic activity in man. Hypertension 1999; 34: 398-402.
17. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke? Mov Disord 2001; 16: 119-123.
18. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008; 55: 310-318.
19. Pathak A, Senard JM. Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology, and management. Expert Rev Neurother 2006; 6: 1173-1180.
20. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009; 15(Suppl 3): S224-S232.
21. Castilla-Guerra L, Fernandez-Moreno MD. Update on the management of hypertension for secondary stroke prevention. Eur Neurol 2012; 68: 1-7.
22. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke 2000; 31: 2307-2313.
23. Fertl E, Doppelbauer A, Auff E. Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors. J Neural Transm Park Dis Dement Sect 1993; 5: 157-161.
24. Toth MJ, Fishman PS, Poehlman ET. Free-living daily energy expenditure in patients with Parkinson's disease. Neurology 1997; 48: 88-91.
25. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Muller T. Hyperhomocysteinaemia in Parkinson's disease. J Neurol 1998; 245: 811-812.
26. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in parkinson's disease. Eur Neurol 1998; 40: 225-227.
27. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002; 51: 285-289.